Díez-Campelo, MaríaLorenzo, Jose IItzykson, RaphaelRojas, Silvia MBerthon, CélineLuño, ElisaBeyne-Rauzy, OdilePerez-Oteyza, JaimeVey, NorbertBargay, JoanPark, SophieCedena, TeresaBordessoule, DominiqueMuñoz, Juan AGyan, EmmanuelSuch, EsperanzaVisanica, SorinLópez-Cadenas, Félixde Botton, StéphaneHernández-Rivas, Jesús MAme, ShantiStamatoullas, AspasiaDelaunay, JacquesSalanoubat, CeliaIsnard, FrançoiseGuieze, RomainPérez Guallar, JoanBadiella, LlorencSanz, GuillermoCañizo, ConsueloFenaux, Pierre2023-01-252023-01-252018-04-02http://hdl.handle.net/10668/12302Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P enazacitidinechromosome 7 abnormalitieshigh risk MDStime-dependent analysisAgedAzacitidineChromosome AberrationsChromosomes, Human, Pair 7Disease-Free SurvivalFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesRegistriesRetrospective StudiesRisk FactorsSurvival Rateresearch article29611196open access10.1111/bjh.151901365-2141https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.15190